As an investor, deciding whether to invest in an IPO can often be challenging. If you are confused and worried about whether to Apply for the Anlon Healthcare IPO, do not worry. Here are 10 important key points and an in-depth, detailed Anlon Healthcare IPO review that will help you make the decision.
Strengths and Weaknesses of Anlon Healthcare IPO
Strengths:
- Over the years, the company has shown a strong product portfolio and a scalable business.
- The company consists of a strong, experienced team who have played a significant role in shaping and developing the business.
- Anlon Healthcare is committed to maintaining the quality standards by incorporating in-house testing, quality control, and quality assurance.
- At their manufacturing facility, they have quality check systems to ensure consistent quality, efficiency, and safety.
Weaknesses:
- The company needs to follow the strict technical specifications, quality standards, and undergo regular inspections and audits in order to fulfill the customer’s requirements. If they fail to meet these requirements can badly impact the business, like they may lose the business from them or face order cancellation.
- Anlon Healthcare mostly generates its revenue from via limited number of customers; losing any of those customers can negatively impact the business, financial condition, and cash flows.
- The company generates its revenue from selling its products to different segments of the pharmaceutical industry. In case if demand for their products falls, or a new drug makes them outdated can badly affect the overall condition and cash flow.
- In previous years, the company has experienced negative cash flows.
Anlon Healthcare IPO Details
| IPO Size: | ₹121.03 crores |
| Offer-for-sale: | No Offer-for-Sale |
| Fresh issue: | ₹121.03 crores |
| Price band: | ₹86 to ₹91 |
| Subscription: | Opens on August 26, 2025, and the closing date is August 29, 2025 |
| Purpose of IPO: | Fresh Issue |
- Anlon Healthcare IPO Open and closing dates?
The Anlon Healthcare IPO will open for subscription on August 26, 2025, and close on August 29, 2025.
- What is the size of the Anlon Healthcare IPO?
The company planned to raise around ₹121.03 crores in funds via an IPO. This IPO comprises only a fresh issue of ₹121.03 crores with a face value of ₹10 each.
- What are the subscription details of the Anlon Healthcare IPO?
The Anlon Healthcare IPO price range is set at ₹86 to ₹91 per share. In this IPO, a total of 164 shares were available in 1 lot size for the minimum Retail category, and for the maximum retail category, 2,132 shares in 13 lot sizes were available. For the S-HNI Minimum category, 2,296 shares were available in 14 lot sizes. While for the B-HNI Minimum category, 11,152 shares were available in 68 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,924 and maximum investment of ₹1,94,012.
- Small HNI (S-HNI): Minimum investment of ₹2,08,936.
- Big HSI (S-HNI): A minimum investment of ₹10,14,832 is required.
- What is the Anlon Healthcare IPO listing Date?
Anlon Healthcare is a Mainboard IPO shares will be listed on September 3, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).
- What are the objectives of the Anlon Healthcare IPO Issue?
The objective behind raising funds via a fresh issue is to utilize the funding for capital expenditure requirements for the Proposed Expansion. Some of the funds will be used for the Full or partial repayment and/or prepayment of certain outstanding secured borrowing (term loan)availed by the Company. Lastly, the remaining funds will be used for the General corporate purposes.
- About Anlon Healthcare
Incorporated in 2013, Anlon Healthcare Limited is one of the leading chemical manufacturing companies involved in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). APIs are used across multiple healthcare products, including tablets, capsules, ointments, syrups, nutraceuticals, personal care items, and animal health products. The company’s portfolio covers pharmaceutical intermediates, active pharmaceutical ingredients (APIs), nutraceutical APIs, and specialty ingredients for personal care and veterinary applications.
Anlon Healthcare is also one of the few Indian companies manufacturing loxoprofen sodium dihydrate, an API commonly prescribed for severe pain management such as arthritis, back pain, frozen shoulder, dental pain, and post-surgical recovery. As of January 31, 2025, the company employed 105 people (excluding trainees) along with 8 contract workers. At the time of filing its DRHP, it offered 65 commercial products, with another 28 at the pilot stage and 49 undergoing laboratory testing.
- Anlon Healthcare IPO Financials
The company reported revenue of ₹66.69 crores in 2024 against ₹113.12 crores in 2023. The company reported a profit of ₹9.66 crores in 2024 against a profit of ₹5.82 crores in 2023.
- Anlon Healthcare IPO Promoters
Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia are the promoters of the company.
- Who are the Anlon Healthcare IPO lead managers and registrar?
Interactive Financial Services Ltd is the lead manager of Anlon Healthcare, while KFin Technologies Limited is the registrar to the issue.
- Should you apply or not for the Anlon Healthcare IPO?
The Anlon Healthcare IPO looks promising as the company manufactures pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”), a raw material used in pharmaceutical formulations, tablets, capsules, ointments, and syrups. Moreover, Anlon Healthcare is one of India’s few manufacturers of loxoprofen sodium dihydrate.
As of now, the company’s portfolio comprises 65 commercialised products and 28 products. The good quality systems and plans to use the IPO money for expansion, working capital, and reducing debt make them a trusted company to invest in. If we talk about the company’s finances, in FY23-24, the revenue fell from ₹112 crore to ₹66 crore, however, the Profit After Tax grew from ₹5.8 crore to ₹9.6 crore, respectively.
Now, if you ask whether you should apply for the Anlon Healthcare IPO, investors seeking exposure to pharmaceutical intermediates and looking for potential listing gains or long-term holding may find this IPO worth considering.
This implies that Anlon Healthcare Limited may offer high returns and can provide excellent long-term gains. However, in the end, we always recommend doing a good financial background check on the company to avoid potential risks and losses. Please invest cautiously and at your own risk.
